Jonathan M Philpott1, Christian W Zemlin2, James L Cox3, Mack Stirling4, Michael Mack5, Robert L Hooker6, Allen Morris7, David A Heimansohn8, James Longoria9, Divyakant B Gandhi10, Patrick M McCarthy11. 1. Department of Surgery, Eastern Virginia Medical School, Norfolk, Virginia; Mid-Atlantic Thoracic Surgeons, Sentara Heart Hospital, Norfolk, Virginia. 2. Department of Electrical and Computer Engineering, Old Dominion University, Norfolk, Virginia; Center for Bioelectrics, Old Dominion University, Norfolk, Virginia. Electronic address: czemlin@odu.edu. 3. Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, Missouri. 4. Munson Medical Center, Traverse City, Michigan. 5. Baylor Heart Hospital, Plano, Texas. 6. Spectrum Health, Butterworth Hospital, Grand Rapids, Michigan. 7. Mercy Heart Institute, Sacramento, California. 8. Heart Center of Indiana, Indianapolis, Indiana. 9. Sutter Heart Institute, Sacramento, California. 10. McLaren Greater Lansing, Lansing, Michigan. 11. Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: The Cox Maze-IV procedure (CMP-IV) has replaced the Cox Maze-III procedure as the most common approach for the surgical treatment of atrial fibrillation (AF). The Food and Drug Administration-regulated AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation (ABLATE) trial sought to demonstrate the safety and efficacy of the CMP-IV performed with the Synergy ablation system (AtriCure, Inc, Cincinnati, OH). METHODS:Fifty-five patients (aged 70.5 ± 9.3 years), 92.7% of whom had nonparoxysmal AF, underwent CMP-IV to terminate AF during a concomitant cardiac surgical procedure. Lesions were created using the AtriCure Synergy bipolar radiofrequency ablation system. All patients were seen for follow-up visits after 30 days, 3 months, and 6 months, with 24-hour Holter monitoring at 6 months. Late evaluation was performed by 48-hour Holter monitoring at an average of 21 months. RESULTS: The primary efficacy endpoint, absence of AF (30 seconds or less) at 6-month follow-up off antiarrhythmic medications (Heart Rhythm Society definition), indicated 76% (38 of 50) were AF free (95% confidence interval: 62.6% to 85.7%). The primary safety endpoint, the rate of major adverse events within 30 days, was 9.1% (5 of 55; 95% confidence interval: 3.9% to 19.6%), with 3.6% mortality (2 of 55). Secondary efficacy endpoints included being AF free with antiarrhythmic drugs (6 months, 84%; 21 months, 75%), successful pulmonary vein isolation (100%), and AF burden at 6 and 21 months. The results, together with those for the secondary safety endpoint (6-month major adverse events), demonstrated that the Synergy system performs comparably to the cut-and-sew Cox Maze-III procedure. CONCLUSIONS: The CMP-IV using the AtriCure Synergy system was safe and effective for cardiac surgical patients who had persistent and longstanding persistent AF.
RCT Entities:
BACKGROUND: The Cox Maze-IV procedure (CMP-IV) has replaced the Cox Maze-III procedure as the most common approach for the surgical treatment of atrial fibrillation (AF). The Food and Drug Administration-regulated AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation (ABLATE) trial sought to demonstrate the safety and efficacy of the CMP-IV performed with the Synergy ablation system (AtriCure, Inc, Cincinnati, OH). METHODS: Fifty-five patients (aged 70.5 ± 9.3 years), 92.7% of whom had nonparoxysmal AF, underwent CMP-IV to terminate AF during a concomitant cardiac surgical procedure. Lesions were created using the AtriCure Synergy bipolar radiofrequency ablation system. All patients were seen for follow-up visits after 30 days, 3 months, and 6 months, with 24-hour Holter monitoring at 6 months. Late evaluation was performed by 48-hour Holter monitoring at an average of 21 months. RESULTS: The primary efficacy endpoint, absence of AF (30 seconds or less) at 6-month follow-up off antiarrhythmic medications (Heart Rhythm Society definition), indicated 76% (38 of 50) were AF free (95% confidence interval: 62.6% to 85.7%). The primary safety endpoint, the rate of major adverse events within 30 days, was 9.1% (5 of 55; 95% confidence interval: 3.9% to 19.6%), with 3.6% mortality (2 of 55). Secondary efficacy endpoints included being AF free with antiarrhythmic drugs (6 months, 84%; 21 months, 75%), successful pulmonary vein isolation (100%), and AF burden at 6 and 21 months. The results, together with those for the secondary safety endpoint (6-month major adverse events), demonstrated that the Synergy system performs comparably to the cut-and-sew Cox Maze-III procedure. CONCLUSIONS: The CMP-IV using the AtriCure Synergy system was safe and effective for cardiac surgical patients who had persistent and longstanding persistent AF.
Authors: Kristine Broglio; William J Meurer; Valerie Durkalski; Qi Pauls; Jason Connor; Donald Berry; Roger J Lewis; Karen C Johnston; William G Barsan Journal: JAMA Netw Open Date: 2022-05-02
Authors: Marc Gerdisch; Eric Lehr; Gansevoort Dunnington; John Johnkoski; Andrew Barksdale; Manesh Parikshak; Patrick Ryan; Samuel Youssef; Robert Fletcher; Glenn Barnhart Journal: J Card Surg Date: 2022-07-23 Impact factor: 1.778
Authors: Fei Xie; Frency Varghese; Andrei G Pakhomov; Iurii Semenov; Shu Xiao; Jonathan Philpott; Christian Zemlin Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240
Authors: Bo Jiang; Ji-Wei Gu; Yan-Yan Song; Lei Bai; Xu-Dong Liu; Yu-Jing Zhang; Ming-Liang Li; Jian Yang; Li Liu; Yun Wang Journal: Int J Gen Med Date: 2021-05-26